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Existing reports of viral hepatitis, resulting in liver cell death have not been fully
explained with regards to the mechanism of the viral proteins involved. The objective
of the study is to determine if any of the Hepatitis B viral proteins cause changes in
the survival of human hepatocytes and if so by what means. The two main candidates
for inducing survival changes were the precore proteins (HBE) and HBX, both of
which have been reported to accumulate in the liver of patients and to trigger an
immune response. The human liver HepG2 cell line was chosen to study the effect ,of
these proteins during transient expression. The results from this study show that both
viral proteins can induce cell death by an apoptotic mechanism via caspases. HBX
appears to trigger more cell death than HBE, while HBE-induced an initial
proliferation of the cell culture followed by cell death. HBX-induced apoptosis
appears to involve both extrinsic and intrinsic cell death systems through the Fas
3
system and the mitochondria, respectively. There is also a total loss of the PI3K/Akt
pathway surivial signals. The HBE-induced apoptosis appears to be through DNA
damage triggering an intrinsic cell death program, coupled with a partial loss of the
PI3K/Akt pathway that allows GSK313 to be activated, while keeping FHKR inactive.
In both cases, the viral cell death can be prevented using the correct dosage of IL-6
stimulation, while loss of serum or the addition of ethanol can have an overall
positive effect on the viability of HBX and HBE transfected cells. The deaths can
also be prevented in varing degress by the inhibition of MEKI and PPIA/2A
suggesting these pathways are involved probably by cross talking.
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Laporan tentang virus hepatitis yang mengakibatkan kerosakan hati belum lagi
dijelaskan dengan sepenuhnya dalam aspek mekanisma dan peranan protin virus
yang terlibat. Projek ini bertujuan menyiasat sebarang protin virus hepittitis B
yang mempengaruhi kehidupan sel hati manusia dan, jika ada bagaimana protin
tersebut berfungsi. Dua protin yang memainkan peranan penting adalah protin
precore (HBE) dan HBX. Kedua- dua protin tersebut telah dilaporkan terkumpul
di dalam hati pesakit dan akan merangsangkan respon keimunan. Sel kanser
hepatoblastoma, HepG2, telah dipilih untuk menyiasat kesan protin tersebut
semasa transcient ekspesi. Keputusan menunjukan kedua-dua protin virus itu
dapat merangsangkan kematian sel melalui mekanisma yang bergantung kepada
caspase. HBX didapati merangsangkan kematian sel yang banyak berbanding
dengan HBE. Manakala, HBE merangsangkan fasa awal pembahagian sel diikuti
dengan kematian sel. Perangsangan apoptosis oleh HBX melibatkan sistem
kematian sel ekstrinsik dan intrinsik melalui sistem Fas dan mitokondria masing-
masing. Terdapat juga kehilangkan isyarat kehidupan bagi perjalanan PI3K1Akt.
Kematian sel akibat daripada HBE adalah disebabkan oleh kerosakan DNA yang
seterusnya merangsangkan program kematian sel intrinsik. Bersamaan kejadian
tersebut, terdapat kehilangan separa dalam perjalanan PI3K1Akt yang
membolehkan keaktifan GSK3~ tanpa mengaktifkan FHKR. Kesan kematian sel
akibat daripada kedua-dua protin virus ini dapat diterbalikkan dengan sukatan IL-6
tertentu. Manakala, kehilangan serum atau penambahan etanol boleh membawa
kesan positif ke atas viabiliti sel yang dijangkiti HBX dan HBE. Darjah
penyongsangan kematian sel dipengaruhi oleh penyahaktifan MEK 1 dan
PPIAl2A. Kesimpulannya, kedua-dua protin virus tersebut berkerjasama
merangsangkan kematian sel yang dapat dipengaruhi oleh factor-faktor luaran.
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